Applied therapeutics CFO sells shares worth over $150k

© Reuters.

Applied Therapeutics, Inc. (NASDAQ:) Chief Financial Officer Leslie D. Funtleyder has recently sold a significant number of shares in the company. The transaction, which occurred on March 14, involved the sale of 28,727 shares of common stock at an average price of $5.39, netting a total of approximately $154,838.

This sale was not a discretionary transaction by Funtleyder. According to the footnotes in the filing, the shares were sold to cover tax withholding obligations that arose from the vesting and settlement of compensatory Restricted Stock Units. The “sell to cover” transaction is a common method for executives to manage the tax implications of vested equity awards.

The prices at which the shares were sold ranged from $5.37 to $5.7855, indicating that the sale was executed in multiple transactions to achieve the weighted average price reported. Following this sale, Funtleyder still owns 308,421 shares of Applied Therapeutics, indicating a continued vested interest in the company’s performance.

Investors often monitor the buying and selling activities of company insiders as it may provide insights into their perspective on the company’s future. However, it is important to note that transactions related to tax obligations can be part of standard compensation arrangements and may not necessarily signal a change in an executive’s outlook on the company.

Applied Therapeutics continues to focus on the development of novel treatments in areas of high unmet medical need, with ongoing research and development efforts. As with any insider transaction, investors are encouraged to consider the context of the sale and to look at a broad range of factors when assessing their investment in the company.

InvestingPro Insights

As Applied Therapeutics, Inc. (NASDAQ:APLT) navigates through its financial and developmental milestones, real-time data from InvestingPro offers a snapshot of the company’s current market standing:

• The company’s market capitalization stands at $631.09 million, reflecting its valuation in the biotechnology space.
• Applied Therapeutics is currently trading at a price-to-earnings (P/E) ratio of -4.30, with an adjusted P/E ratio for the last twelve months as of Q4 2023 at -5.27, indicating that the market is pricing the company’s shares in anticipation of future earnings.
• Despite a challenging gross profit margin of -439.43% for the same period, the company has experienced a significant year-to-date price total return of 79.7%, showcasing a strong market performance in the short term.

Delving into the InvestingPro Tips, two key insights emerge that align closely with the context of the CFO’s recent share sale:

• Applied Therapeutics operates with a moderate level of debt and has been facing challenges with short-term obligations exceeding liquid assets, which could be a factor in the CFO’s decision to sell shares for tax withholding purposes.
• The company’s stock price movements have been quite volatile, with a high return over the last year. This could suggest that the timing of the share sale by the CFO may also be influenced by market conditions and stock performance.

It is essential for investors to consider these metrics and tips alongside insider transactions to gain a more comprehensive understanding of Applied Therapeutics’ financial health and market position. For those looking to delve deeper, InvestingPro provides a suite of additional tips, with 11 more insights available to help inform investment decisions. Interested readers can access these insights and benefit from an additional 10% off a yearly or biyearly Pro and Pro+ subscription using the coupon code PRONEWS24.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.